• P-ISSN2233-4203
  • E-ISSN2093-8950

Article Detail

Home > Article Detail
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

Electrospray-Mass Spectrometric Analysis of Plasma Pyrophosphates Separated on a Multi-Modal Liquid Chromatographic Column

Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2011, v.2 no.4, pp.92-95
https://doi.org/10.5478/MSL.2011.2.4.092
Lee Su Hyeon (Korea Institute of Science and Technology)
Lee Jeongae (Korea Institute of Science and Technology)
Won-Yong Lee (Yonsei University)
Chung Bong Chul (Korea Institute of Science and Technology)
Choi Man Ho (Korea Institute of Science and Technology)
  • Downloaded
  • Viewed

Abstract

Pyrophosphates are the key intermediates in the biosynthesis of isoprenoids, and their concentrations could revealthe benefits of statins in cardiovascular diseases. Quantitative analysis of five pyrophosphates, including isopentenyl pyrophosphate(IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranylpyrophosphate (GGPP), was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in negative ionizationmode. After dilution with methanol, samples were separated on a 3 μm particle multi-modal C18 column (50 × 2 mm)and quantified within 10 min. The gradient elution consists of 10 mM ammonium bicarbonate and 0.5% triethylamine (TEA) inwater and 0.1% TEA in 80% acetonitrile was used at the flow rate of 0.4 mL/min. Overall recoveries were 51.4-106.6%, whilethe limit of quantification was 0.05 μg/mL for GPP and FPP and 0.1 μg/mL for IPP, DMAPP, and GGPP. The precision (% CV)and accuracy (% bias) of the assay were 1.9-12.3% and 89.6-111.8%, respectively, in 0.05-10 μg/mL calibration ranges (R2 > 0.993). The devised LC-MS/MS technique with the multi-modal C18 column can be used to estimate the biological activity of pyrophosphatesin plasma and may be applicable to cardiovascular events with cholesterol metabolism as well as the drug efficacy of statins.

keywords
Pyrophosphate Isoprenoids LC-MS Multi-modal column Cardiovascular disease Statins


Reference

1

Henneman, L. (2008). . Anal. Biochem, 383, 18-.

2

Henneman, L. (2011). . Biochim. Biophys. Acta, 1811, 227-.

3

Jauhiainen, M. (2009). . J. Chromatogr. B, 877, 2967-.

4

Bajad, S. U.. (2006). . J. Chromatogr. A, 1125, 76-.

5

Nürenberg, G. (2011). . Anal. Bioanal. Chem, , -. http://dx.doi.org/10.1007/s00216-011-5262-2..

6

Hooff, G. P. (2010). . Anal. Bioanal. Chem, 398, 1801-.

7

O’Neill, W. C.. (2010). . Nephrol. Dial. Transplant, 25, 187-.

8

Tong, H. (2008). . Anal. Biochem, 378, 138-.

9

Saisho, Y. (1997). . Anal. Biochem, 252, 89-.

10

Bicker, W. (2006). . Anal. Chem, 78, 5884-.

11

Stevenson, P. G. (2011). G. J. Chromatogr. A 2011. J. Chromatogr, 1218, 1822-.

12

Ha, Y. W. (2009). . J. Chromatogr. B, 877, 4125-.

13

Moon, J. Y. (2009). . J. Am. Soc. Mass Spectrom, 20, 1626-.

14

Pont, F. (2001). . J. Anal. Chem, 73, 3562-.

Submission Date
2011-12-08
Revised Date
2011-12-14
Accepted Date
2011-12-15
상단으로 이동

Mass Spectrometry Letters